Abbott Laboratories (ABT) : Notis-mcconarty Edward scooped up 1,625 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 75,895 shares of Abbott Laboratories which is valued at $3,419,070.Abbott Laboratories makes up approximately 2.32% of Notis-mcconarty Edward’s portfolio.
Other Hedge Funds, Including , Scout Investments boosted its stake in ABT in the latest quarter, The investment management firm added 3,300 additional shares and now holds a total of 15,400 shares of Abbott Laboratories which is valued at $693,770. Abbott Laboratories makes up approx 0.02% of Scout Investments’s portfolio.Texan Capital Management boosted its stake in ABT in the latest quarter, The investment management firm added 213 additional shares and now holds a total of 6,096 shares of Abbott Laboratories which is valued at $274,015. Abbott Laboratories makes up approx 0.12% of Texan Capital Management’s portfolio. Quantitative Systematic Strategies added ABT to its portfolio by purchasing 9,417 company shares during the most recent quarter which is valued at $421,411. Abbott Laboratories makes up approx 0.18% of Quantitative Systematic Strategies’s portfolio.Greylin Investment Mangement Inc boosted its stake in ABT in the latest quarter, The investment management firm added 8,450 additional shares and now holds a total of 46,605 shares of Abbott Laboratories which is valued at $2,035,240. Abbott Laboratories makes up approx 0.45% of Greylin Investment Mangement Inc’s portfolio.
Abbott Laboratories opened for trading at $45.2 and hit $45.23 on the upside on Monday, eventually ending the session at $45.15, with a gain of 0.24% or 0.11 points. The heightened volatility saw the trading volume jump to 65,25,830 shares. Company has a market cap of $66,370 M.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.